Clinical impact of biofire gastrointestinal panel testing for hospitalised children with acute gastroenteritis

Aviv Sever1, Haim Ben Zvi2,3, Shirel Barnea Melamed1

  • 1Department of Pediatrics C, Schneider Children's Medical Center, Petach Tikva, Israel.

Insights

The BioFire FilmArray Gastrointestinal Panel (FGP) test significantly increased pathogen identification in hospitalized children with diarrhea. This diagnostic tool impacted clinical decisions, particularly for healthy and transplant patients.

Area of Science:

  • Pediatric Infectious Diseases
  • Clinical Microbiology
  • Diagnostic Technology

Background:

  • Diarrhoeal episodes are common in hospitalised children.
  • Accurate and rapid pathogen identification is crucial for effective treatment.
  • Conventional methods may have limitations in detecting diverse gastrointestinal pathogens.

Purpose of the Study:

  • To evaluate the clinical impact of BioFire FilmArray Gastrointestinal Panel (FGP) testing.
  • To assess the utility of FGP testing in real-life diarrhoeal episodes in paediatric patients.
  • To determine if FGP testing influences clinical decision-making and antibiotic prescriptions.

Main Methods:

  • Retrospective observation of hospitalised children with diarrhoea between October 2018 and September 2020.
  • Collection of demographic, clinical, and stool test data.
  • Evaluation of clinical impact by assessing changes in antibiotic prescriptions post-FGP testing.

Main Results:

  • FGP testing identified significantly more pathogens (75) compared to conventional methods (25) (p < 0.05).
  • Commonly identified pathogens by FGP included Campylobacter, Shigella, Rotavirus, Giardia lamblia, and Cryptosporidium.
  • Clinical impact was observed in 12% of cases, with higher rates in previously healthy (19%) and solid organ-transplanted children (15%).

Conclusions:

  • BioFire FilmArray Gastrointestinal Panel (FGP) testing enhances pathogen detection in hospitalised children with diarrhoea.
  • FGP testing can positively impact clinical decisions, including antibiotic prescribing.
  • The diagnostic yield and clinical utility of FGP are particularly notable in immunocompromised and previously healthy paediatric populations.
Abstract